ACHL | Achilles Therapeutics plc

Index- P/E- EPS (ttm)-1.81 Insider Own5.96% Shs Outstand39.73M Perf Week1.74%
Market Cap40.51M Forward P/E- EPS next Y-1.21 Insider Trans0.00% Shs Float38.91M Perf Month24.65%
Income-71.30M PEG- EPS next Q-0.41 Inst Own73.60% Short Float / Ratio0.04% / 0.08 Perf Quarter-4.93%
Sales- P/S- EPS this Y14.70% Inst Trans0.50% Short Interest0.01M Perf Half Y-49.63%
Book/sh4.66 P/B0.22 EPS next Y13.60% ROA-31.20% Target Price8.80 Perf Year-59.47%
Cash/sh3.98 P/C0.26 EPS next 5Y3.20% ROE-34.90% 52W Range0.75 - 3.45 Perf YTD13.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.51% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low35.65% ATR0.07
Employees234 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)56.49 Volatility7.28% 7.48%
OptionableNo Debt/Eq0.00 EPS Q/Q1.30% Profit Margin- Rel Volume0.20 Prev Close1.03
ShortableYes LT Debt/Eq0.00 EarningsMar 07 BMO Payout- Avg Volume180.60K Price1.02
Recom1.80 SMA202.73% SMA509.68% SMA200-34.26% Volume35,916 Change-1.22%
Date Action Analyst Rating Change Price Target Change
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
May-21-23 10:03AM
May-10-23 07:15AM
Apr-25-23 06:00PM
09:45AM Loading…
Apr-22-23 09:45AM
Apr-17-23 08:00AM
Mar-07-23 07:00AM
Feb-02-23 09:40AM
Jan-17-23 09:40AM
Dec-20-22 08:30AM
Dec-06-22 06:00AM
Nov-30-22 06:05PM
Nov-22-22 08:00AM
Nov-13-22 07:48AM
07:00AM Loading…
Nov-08-22 07:00AM
Nov-01-22 12:00PM
Oct-06-22 08:30AM
Sep-07-22 01:15PM
Aug-31-22 12:53PM
Aug-26-22 01:34PM
Aug-25-22 11:53AM
Aug-24-22 01:33PM
Aug-23-22 01:53PM
Aug-19-22 12:32PM
Aug-16-22 10:09AM
Aug-09-22 07:00AM
Aug-01-22 06:00AM
Jul-21-22 08:00AM
Jun-30-22 08:00AM
08:30AM Loading…
Jun-21-22 08:30AM
Jun-06-22 08:40AM
May-10-22 07:00AM
May-09-22 07:00AM
May-04-22 08:00AM
May-03-22 08:00AM
Apr-14-22 11:27AM
Apr-12-22 07:30AM
Apr-05-22 08:00AM
Apr-04-22 08:00AM
Mar-08-22 08:00AM
Mar-01-22 09:00AM
Feb-07-22 07:30AM
Jan-13-22 07:30AM
Dec-28-21 04:09AM
Dec-21-21 08:00AM
Dec-20-21 08:00AM
Dec-09-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 08:15AM
Nov-09-21 08:00AM
Oct-22-21 07:30AM
Oct-12-21 08:00AM
Oct-01-21 08:00AM
Sep-29-21 06:15AM
Sep-02-21 08:30AM
Aug-25-21 08:00AM
Aug-10-21 07:00AM
Jul-26-21 03:00PM
Jul-01-21 08:00AM
Jun-04-21 09:00AM
May-11-21 07:00AM
May-06-21 08:00AM
May-05-21 08:30AM
May-03-21 08:00AM
Apr-10-21 08:30AM
Apr-06-21 04:01PM
Mar-31-21 02:01PM
Mar-30-21 07:00PM
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.